Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease

M K Wilson, E Pujade-Lauraine, D Aoki, M R Mirza, D Lorusso, A M Oza, A du Bois, I Vergote, A Reuss, M Bacon, M Friedlander, D Gallardo-Rincon, F Joly, S-J Chang, A M Ferrero, R J Edmondson, P Wimberger, J Maenpaa, D Gaffney, R ZangA Okamoto, G Stuart, K Ochiai, participants of the Fifth Ovarian Cancer Consensus Conference

    198 Citationer (Scopus)

    Abstract

    This manuscript reports the consensus statements regarding recurrent ovarian cancer (ROC), reached at the fifth Ovarian Cancer Consensus Conference (OCCC), which was held in Tokyo, Japan, in November 2015. Three important questions were identified: (i) What are the subgroups for clinical trials in ROC? The historical definition of using platinum-free interval (PFI) to categorise patients as having platinum-sensitive/resistant disease was replaced by therapy-free interval (TFI). TFI can be broken down into TFIp (PFI), TFInp (non-PFI) and TFIb (biological agent-free interval). Additional criteria to consider include histology, BRCA mutation status, number/type of previous therapies, outcome of prior surgery and patient reported symptoms. (ii) What are the control arms for clinical trials in ROC? When platinum is considered the best option, the control arm should be a platinum-based therapy with or without an anti-angiogenic agent or a poly (ADP-ribose) polymerase (PARP) inhibitor. If platinum is not considered the best option, the control arm could include a non-platinum drug, either as single agent or in combination. (iii) What are the endpoints for clinical trials in ROC? Overall survival (OS) is the preferred endpoint for patient cohorts with an expected median OS < or = 12 months. Progression-free survival (PFS) is an alternative, and it is the preferred endpoint when the expected median OS is > 12 months. However, PFS alone should not be the only endpoint and must be supported by additional endpoints including pre-defined patient reported outcomes (PROs), time to second subsequent therapy (TSST), or time until definitive deterioration of quality of life (TUDD).

    OriginalsprogEngelsk
    TidsskriftAnnals of Oncology
    Vol/bind28
    Udgave nummer4
    Sider (fra-til)727-732
    Antal sider6
    ISSN0923-7534
    DOI
    StatusUdgivet - 1 apr. 2017

    Fingeraftryk

    Dyk ned i forskningsemnerne om 'Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease'. Sammen danner de et unikt fingeraftryk.

    Citationsformater